Beauty Health shares fall 6% after earnings miss, cautious FY26 outlook
Revenue beat of 20% overshadowed by EPS shortfall as company projects second-half recovery
The Beauty Health Company shares fell 5.8% to $1.06 in pre-market trading Thursday after the aesthetic products maker reported fourth-quarter results that showed a top-line beat but bottom-line shortfall, alongside fiscal 2026 guidance that leans on a second-half recovery.
The Signal Hill, California-based company reported fourth-quarter revenue of $82.4 million, exceeding analyst estimates of $68.3 million by 20.6%. However, earnings per share came in at a loss of $0.06, wider than the expected loss of $0.05, representing a 20% miss on the bottom line.
Despite the earnings miss, the company demonstrated significant operational improvements. Adjusted EBITDA reached $15.0 million in the fourth quarter, up 67% year-over-year, while full-year adjusted EBITDA surged 267% to $45.1 million. Gross margins expanded dramatically to 65.3%, up from 54.5% in the prior year, indicating progress in operational efficiency.
"We delivered strong margin expansion and profitability improvements throughout fiscal 2025, reflecting our strategic focus on operational excellence," the company stated in its earnings announcement, according to regulatory filings. "Our adjusted EBITDA growth of 267% demonstrates the effectiveness of our initiatives."
For fiscal 2026, Beauty Health provided guidance of net sales between $285 million and $305 million, with adjusted EBITDA projected at $35 million to $45 million. The outlook suggests the company expects a recovery in the second half of the year, which investors appeared to view cautiously given the softer first-half trajectory.
The stock's decline extends what has been a challenging period for shareholders. Beauty Health shares are currently trading near their 52-week low of $0.78, down sharply from a 52-week high of $2.69 reached last year. The company now has a market capitalization of approximately $144 million.
Analyst sentiment remains cautious. Beauty Health carries an average price target of $2.03, representing potential upside of 92% from current levels, though the consensus rating leans toward hold with five analysts rating it a hold, one a buy, and two a strong sell, according to market data. Institutional investors own 90.5% of shares, indicating high institutional concentration despite the recent volatility.
The Beauty Health Company, known for its Hydrafacial skincare systems, operates in the competitive aesthetic products market. The company's products are used by skincare professionals and dermatologists for treatments including cleansing, exfoliation, extraction, and hydration.
The mixed earnings report highlights the challenges facing small-cap consumer discretionary companies in the current economic environment. While revenue growth and margin expansion demonstrate operational progress, investor expectations for near-term profitability and growth appear to be weighing on the stock's valuation. The company's ability to execute on its second-half recovery plan will be critical to reversing the recent downward trajectory of its shares.
Management's commentary around fiscal 2026 emphasized confidence in the company's strategic initiatives and market position, but the conservative first-half outlook suggests near-term headwinds may persist. Investors will be watching upcoming quarterly results closely for evidence that the company can achieve the accelerated growth implied in the back half of its guidance.